It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2018
  5. Otsuka subsidiary Avanir and Optinose agree to terminate license agreement for migraine treatment ONZETRA®Xsail®

December 11, 2018

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

Otsuka subsidiary Avanir and Optinose agree to terminate license agreement
for migraine treatment ONZETRA®Xsail®

Otsuka Pharmaceutical Co., Ltd. today announces that its U.S.-based indirect subsidiary Avanir Pharmaceuticals, Inc. has agreed with Optinose, Inc. to return to Optinose the rights in North America to ONZETRA®Xsail® for the acute treatment of migraines in adults.

Avanir comprehensively reevaluated the U.S. migraine medication market. As a result, the decision was made to terminate the licensing agreement.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases